
    
      In a double-blind trial, eligible adults with post-infectious IBS with increased intestinal
      permeability were randomly assigned to receive either glutamine (5 g three times daily) or
      placebo for eight weeks. The primary end point was the proportion of patients who had a
      reduction of â‰¥50 on the Irritable Bowel Severity Scoring System (IBS-SS).
    
  